Eight Drugs a Week Podcast
We gather the two chairs of the upcoming IATDMCT annual meeting in Singapore, Sophie Stocker and Jana Stojanova, plus Cindy Lau, who contribute to the organization of the young scientists’ part of the event to discuss the content, urbi et orbi, of our annual meeting. In this episode we’ll hear about: The journey from an inspiration to the building of a real conference dedicated to creating innovative solutions in therapeutic drug monitoring and clinical toxicology. The keynote lectures, main topics and hosts selected highlights of a scientific program going from biosensors applications...
info_outlineEight Drugs a Week Podcast
We gather the two chairs of the upcoming IATDMCT annual meeting in Singapore, Sophie Stocker and Jana Stojanova, plus Cindy Lau, who contribute to the organization of the young scientists’ part of the event to discuss the content, urbi et orbi, of our annual meeting. In this episode we’ll hear about: The journey from an inspiration to the building of a real conference dedicated to creating innovative solutions in therapeutic drug monitoring and clinical toxicology. The keynote lectures, main topics and hosts selected highlights of a scientific program going from biosensors applications...
info_outlineEight Drugs a Week Podcast
Pharmacogenetics now surrounds us and is an efficient tool to prevent disease or to guide drug therapy. By studying polymorphisms in the genes coding for metabolism enzymes and drug transporters, we can have clues to help choose the right drug or adjust drug dosage. Not to mention that pharmacogenetics is the ideal companion for therapeutic drug monitoring for a comprehensive treatment optimization. Treatment failure and adverse drug reactions may, at least partly, be explained with pharmacogenetics and we have never been so close to large-scale implementation of this strategy. In this...
info_outlineEight Drugs a Week Podcast
Given we traditionally only monitored particular antibiotics to spare toxicity, and that beta lactams were widely considered such safe drugs, it was once difficult to imagine this drug class would become important TDM candidates. A bit more than a decade ago we started to see the first reports about augmented renal clearance in critically ill patients, often in situations in which antibiotic treatment was crucial, such as sepsis. TDM of beta lactams in the critical care is now recognised as a valuable tool to ensure adequate drug exposure and optimise therapeutic outcomes for these vulnerable...
info_outlineEight Drugs a Week Podcast
This time, it’s the right time - not a second time, but a unique time - to take the road to Banff, Canada, for the This time, following a very successful virtual edition in 2020, we are very glad to be meeting in person. And what a place to meet! - surrounded by Banff’s mountainous splendour. We are so grateful the congress organizing committee accepted the mission to make the show happen again, and we acknowledge the incredible work they’ve put behind two wonderful congresses. We hope attendees will be inspired by the location, and we are certain it will be a very special IATDMCT...
info_outlineEight Drugs a Week Podcast
There was a time when we performed laborious pharmacokinetic hand calculations to tailor drug dosages and regimens – a practice that can still be useful for those brave enough to perform logarithmic calculator manipulations. These days, we are fortunate to have an increasing number of software tools to help us with the task, however many rely on population pharmacokinetic models typically built with relatively small data sets, and often necessarily representing subpopulations with niche requirements. Tomorrow, our work will no doubt be helped by artificial intelligence and machine learning...
info_outlineEight Drugs a Week Podcast
This episode we're excited to introduce you to the young guns, the bright minds of the Young Scientist Committee of the IATDMCT, who are making waves in this ever-evolving field. Our guests are Lea Wagmann, Hualin Cai, and Sumith Mathew, each bringing their unique perspectives and experiences from Germany, China, and India, respectively. From their early inspirations to their current endeavours, we'll uncover what drives them and the impact they're making on the future of pharmacology and toxicology. We’ll delve into their expectations for the years ahead, exploring the forefront of...
info_outlineEight Drugs a Week Podcast
This episode is about a fairly recent development in TDM and clinical toxicology that has huge potential, which has actually been used for many decades. It was recently the 50th anniversary of the Guthrie method, where dried blood spots are used to screen inborn errors of metabolism in neonatal infants. Thanks to instrumental developments, dried blood spots, and more generally microsampling approaches, have been increasingly applied to quantify a wide range of drug entities. Although these approaches offer plenty of novel opportunities in our field, they are not without challenges and...
info_outlineEight Drugs a Week Podcast
The recent congress in Oslo was a huge success. We were very glad to catch up with colleagues and hear about some really excellent science. We also bumped into Steve Wong and Phil Walson, first and third presidents of the IATDMCT, and we were delighted they obliged us with an interview about the origins of the Association. Like with any good origin story, Steve and Phil are true superheroes. Both have held numerous leadership positions in their professions and in professional associations, achieved international cooperation agreements, and advocated nationally and internationally for...
info_outlineEight Drugs a Week Podcast
In this bonus episode, we delve into the upcoming that will take place September 24th to 27th in Oslo, Norway . It promises to be an exciting event with varied and highly novel sessions. Joining us today are esteemed IATDMCT scientists and local members of the congress organizing committee: Stein Bergan, Ida Robertson, and Anders Åsberg. We delve into their motivations to host the congress and discuss the inspiration behind the theme: 'Personalized under the Northern Sky.' Our guests elaborate on how they will weave this overarching theme through the whole event. We explore some captivating...
info_outlineThis episode is about the TDM of anticancer therapies, a space where there is a sense of frustration about body-size based dosing, but while concentration-based promises to make a difference to clinical care, it still feels that progress has been less than satisfying. Florian opens the episode with an ode to oncologists, a song from the heart to say: ‘We can work it out!’
Our guests today are Dirk Jan Moes and Vikram Gota, both very active in ‘working things out’ in the space, in different corners of the world. We unpack the many challenges but arrive at the conclusion that for TDM in oncology, ‘the future is bright!’
In this episode we hear about:
- Older anticancer drugs: can we do new tricks with old drugs, or have we missed the boat?
- The importance of the drug label and reimbursement for clinical implementation
- Anticancer drugs and clinical contexts where microsampling can enhance implementation
- Financial toxicity: should we be styling ourselves as financial toxicologists!?
- Progress in the paediatric space
- Combining concentration measurement with pharmacogenetics, biomarkers and model informed precision dosing
- Buy-in: the importance of clinical champions and education initiatives
Eight Drugs a Week is supported by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT). The personal views of the hosts and guests do not necessarily reflect the position of the Association.
To join IATDMCT, visit https://www.iatdmct.org/member-join
Subscribe to Eight Drugs a Week on your preferred podcast platform.
About our guests:
Dirk Jan Moes is a Laboratory Hospital Pharmacist and Clinical Pharmacologist, Assistant Professor of Applied Clinical Pharmacometrics at the Department of Clinical Pharmacy and Toxicology at the Leiden University Medical Centre in The Netherlands.
Vikram Gota is an MD, Professor & Officer-in-charge of the Department of Clinical Pharmacology at the Advanced Centre for Treatment Research & Education in Cancer at the Tate Memorial Centre in Mumbai, India.